CG Oncology Announces Data From The Phase 3 BOND-003 Study Evaluating The Efficacy And Safety Of Cretostimogene Monotherapy, Demonstrated 75.2% Complete Response Rate In High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CG Oncology Announces Data From The Phase 3 BOND-003 Study Evaluating The Efficacy And Safety Of Cretostimogene Monotherapy, Demonstrated 75.2% Complete Response Rate In High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CG Oncology 公佈了評估 Cretostimogene 單一療法療效和安全性的 3 期 BOND-003 研究的數據，顯示在高風險、BCG 無反應的非肌肉浸潤性膀胱癌中，完全緩解率爲 75.2%
- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy -
-BOND-003 第 3 階段研究結果顯示，使用新型在研溶瘤免疫療法可在 12 個月內持續持續出現完全反應-
- Company will hold an investor conference call today at 4:30pm EDT -
-公司將於美國東部時間今天下午 4:30 舉行投資者電話會議-
IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 2024. These data were featured today at the Paradigm...
加利福尼亞州爾灣，2024 年 5 月 3 日（GLOBE NEWSWIRE）—— CG Oncology, Inc. 今天宣佈，評估cretost...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。